6-Mar-2026
Stifel Nicolaus Keeps Their Buy Rating on Artivion (AORT)
TipRanks (Thu, 5-Mar 7:48 AM ET)
Wave of Insider Moves Shakes Up Artivion’s Executive Suite
TipRanks (Wed, 4-Mar 9:09 PM ET)
Top Artivion Executives Quietly Cash In on Company Stock
TipRanks (Tue, 3-Mar 9:06 PM ET)
Artivion to Participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference
PRNewswire (Tue, 3-Mar 4:10 PM ET)
Artivion Reports Fourth Quarter and Full Year 2025 Financial Results
PRNewswire (Thu, 12-Feb 4:05 PM ET)
PRNewswire (Mon, 2-Feb 8:00 AM ET)
PRNewswire (Thu, 29-Jan 4:05 PM ET)
Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others. The company's has two reportable segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues. Company operates in North America, EMEA. LATAM, APAC. Maximum revenue is from North America.
Artivion trades on the NYSE stock market under the symbol AORT.
As of March 6, 2026, AORT stock price declined to $37.04 with 325,428 million shares trading.
AORT has a beta of 0.91, meaning it tends to be less sensitive to market movements. AORT has a correlation of 0.12 to the broad based SPY ETF.
AORT has a market cap of $1.75 billion. This is considered a Small Cap stock.
Last quarter Artivion reported $116 million in Revenue and $.17 earnings per share. This fell short of revenue expectation by $-756,574 and exceeded earnings estimates by $.01.
In the last 3 years, AORT traded as high as $48.25 and as low as $11.44.
The top ETF exchange traded funds that AORT belongs to (by Net Assets): IJR, VTI, IWM, VXF, SPSM.
AORT has outperformed the market in the last year with a return of +49.9%, while the SPY ETF gained +18.7%. However, in the most recent history, AORT shares have underperformed the stock market with its stock returning -16.9% in the last 3 month period and -3.4% for the last 2 week period, while SPY has returned -1.7% and -2.5%, respectively.
AORT support price is $36.84 and resistance is $38.89 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AORT shares will trade within this expected range on the day.